Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin.

@article{Yan2009TopoisomeraseIA,
  title={Topoisomerase II\{alpha\}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin.},
  author={Tiandong Yan and Shiwei Deng and Annegret Metzger and Ute G{\"o}dtel-Armbrust and Andrew C. G. Porter and Leszek Wojnowski},
  journal={Molecular cancer therapeutics},
  year={2009},
  volume={8 5},
  pages={
          1075-85
        }
}
Coadministration of the iron chelator dexrazoxane reduces by 80% the incidence of heart failure in cancer patients treated with anthracyclines. The clinical application of dexrazoxane is limited, however, because its ability to inhibit topoisomerase IIα (TOP2A) is feared to adversely affect anthracycline chemotherapy, which involves TOP2A-mediated generation of DNA double-strand breaks (DSB). Here, we investigated the apoptotic effects of dexrazoxane and the anthracycline doxorubicin, alone and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 20 CITATIONS

Restriction of drug transport by the tumor environment

VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Optimizing Cardiovascular Care in Children With Acute Myeloid Leukemia to Improve Cancer-Related Outcomes.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2019

Doxorubicin induced heart failure: Phenotype and molecular mechanisms

  • International journal of cardiology. Heart & vasculature
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES